Jennifer Kelschenbach
Overview
Explore the profile of Jennifer Kelschenbach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
360
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ament S, Campbell R, Lobo M, Receveur J, Agrawal K, Borjabad A, et al.
Mol Psychiatry
. 2024 Jun;
29(12):3950-3961.
PMID: 38879719
Substance use disorders (SUD) and drug addiction are major threats to public health, impacting not only the millions of individuals struggling with SUD, but also surrounding families and communities. One...
2.
Alfar H, Pariser D, Chanzu H, Joshi S, Coenen D, Lykins J, et al.
STAR Protoc
. 2023 Jun;
4(3):102368.
PMID: 37342907
EcoHIV is a model of HIV infection that recapitulates aspects of HIV-1 pathology in mice. However, there are limited published protocols to guide EcoHIV virion production. Here, we present a...
3.
Kim B, Hadas E, Kelschenbach J, Chao W, Gu C, Potash M, et al.
Sci Rep
. 2023 Apr;
13(1):6577.
PMID: 37085605
HIV enters the brain within days of infection causing neurocognitive impairment (NCI) in up to half of infected people despite suppressive antiretroviral therapy. The virus is believed to enter the...
4.
Murphy A, Kelschenbach J, He H, Chao W, Kim B, Volsky D, et al.
Front Immunol
. 2022 Oct;
13:1004985.
PMID: 36275760
Thirty-eight million people worldwide are living with HIV, PWH, a major public health problem. Antiretroviral therapy (ART) revolutionized HIV treatment and significantly increased the lifespan of PWH. However, approximately 15-50%...
5.
Nedelcovych M, Kim B, Zhu X, Lovell L, Manning A, Kelschenbach J, et al.
J Neuroimmune Pharmacol
. 2021 Apr;
16(3):693.
PMID: 33914277
No abstract available.
6.
Dong B, Borjabad A, Kelschenbach J, Chao W, Volsky D, Potash M
Brain Behav Immun Health
. 2020 Jul;
3.
PMID: 32699842
HIV associated neurocognitive impairment afflicts roughly half of infected individuals on antiretroviral therapy. This disease currently has no treatment. We have previously shown that type I interferon is induced by...
7.
Jaureguiberry-Bravo M, Kelschenbach J, Murphy A, Carvallo L, Hadas E, Tesfa L, et al.
J Leukoc Biol
. 2020 Jun;
109(3):675-681.
PMID: 32578908
Approximately 15-40% of people living with HIV develop HIV-associated neurocognitive disorders, HAND, despite successful antiretroviral therapy. There are no therapies to treat these disorders. HIV enters the CNS early after...
8.
Kelschenbach J, He H, Kim B, Borjabad A, Gu C, Chao W, et al.
mBio
. 2019 Jul;
10(4).
PMID: 31266862
HIV causes neurodegeneration and dementia in AIDS patients, but its function in milder cognitive impairments in virologically suppressed patients on antiretroviral therapy is unknown. Such patients are immunocompetent, have low...
9.
Omeragic A, Kara-Yacoubian N, Kelschenbach J, Sahin C, Cummins C, Volsky D, et al.
Sci Rep
. 2019 Jul;
9(1):9428.
PMID: 31263138
The widespread use of combination antiretroviral therapy (cART) has resulted in significantly reduced deaths from HIV-1 associated complications and opportunistic infections. However, it is estimated that up to 50% of...
10.
Nedelcovych M, Kim B, Zhu X, Lovell L, Manning A, Kelschenbach J, et al.
J Neuroimmune Pharmacol
. 2019 Jun;
14(3):391-400.
PMID: 31209775
HIV-associated neurocognitive disorders (HAND) have been linked to dysregulation of glutamate metabolism in the central nervous system (CNS) culminating in elevated extracellular glutamate and disrupted glutamatergic neurotransmission. Increased glutamate synthesis...